After several cancer failures Celldex tries its hand at autoimmune disease, and the market likes it.
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
But data are early, and other groups are also developing less frequent injections for wet AMD.
177Lu-PSMA-617 shows impressive survival results in the Vision study, but early use will be key to fulfilling its potential.
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
The IPF drug shows surprising promise in heart failure with preserved ejection fraction.
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.